Roche declares positive phase I results of its oral GLP-1 receptor agonist CT-996 to treat people with obesit

Roche has announced positive results from two arms of the ongoing phase I ARANOTE trial for CT-996, an investigational, once-daily oral GLP-1 receptor agonist for treating type 2 diabetes and obesity. The data revealed a significant placebo-adjusted mean weight loss of -6.1% in participants with obesity after four weeks (p <0.001). CT-996 was well tolerated with mild gastrointestinal side effects and no treatment discontinuations. It showed stable blood levels regardless of meal timing, offering dosing flexibility.

Obesity, affecting over four billion people worldwide, is linked to serious comorbidities like type 2 diabetes and cardiovascular diseases. The CT-996-201 trial, evaluating CT-996’s safety and efficacy, includes single and multiple ascending dose studies and plans to advance to phase II.

Roche's broader incretin portfolio includes CT-388 and CT-868, addressing obesity, type 2 diabetes, and other conditions. Incretins, now standard in obesity care, may also benefit cardiovascular and kidney health.